Tesamorelin vs IGF-1 LR3
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, Egrifta WR
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) with a chemical modification that protects it from rapid breakdown. It is FDA-approved (brand name Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. Its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online.
Also: Long R3 IGF-1, LR3
IGF-1 LR3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. It is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. Everything below the mechanism section is preclinical work, laboratory use, or community reporting.
Key Comparison Insights
- Tesamorelin is FDA approved, while IGF-1 LR3 remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to IGF-1 LR3 (Preclinical).
Detailed Comparison
| Attribute | Tesamorelin | IGF-1 LR3 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin tells the pituitary gland to release the body's own growth hormone by acting on GHRH receptors, rather than injecting growth hormone directly. Because it works upstream, it produces a more natural, pulsing pattern of growth-hormone release. The molecule is GHRH 1-44 with a trans-3-hexenoic acid group added to the N-terminus, and that modification slows enzymatic degradation so the signal lasts longer than native GHRH. The downstream rise in growth hormone and IGF-1 is what drives the reduction in visceral fat seen in trials. This is a genuinely upstream, receptor-based mechanism, well characterized in human studies. | Natural IGF-1 is almost entirely bound up by IGF binding proteins in circulation, which controls how much is active and gives it a half-life measured in minutes. LR3 makes two changes: an arginine substitution at position 3, and a 13-amino-acid extension on the N-terminus. Together these dramatically reduce binding-protein affinity, so far more of the molecule stays free and active, extending the functional half-life to something on the order of a day rather than minutes. Once free, it activates the IGF-1 receptor, driving protein synthesis, satellite cell activation and cell proliferation in muscle. That same lack of binding-protein regulation is the reason for caution: binding proteins are a control mechanism, and removing the control is the point of the drug and also its main risk. |
| Common Dosing | 2 mg daily (F8: 1.28 mg daily) Once daily | 20-50 mcg daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection. Because of the hypoglycemia risk, timing relative to carbohydrate intake is the main practical consideration reported. |
| Typical Duration | Indefinite for approved indication | Community cycles are typically reported as 4-6 weeks, on the reasoning that receptor downregulation follows longer use |
| Best Time to Take | Before bed (fasted) | With or near a carbohydrate-containing meal |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The approval rests on real randomized, placebo-controlled human trials. The pivotal study by Falutz and colleagues (New England Journal of Medicine, 2007) showed that six months of tesamorelin selectively reduced visceral abdominal fat in HIV patients while improving lipid profiles, without meaningful harm to blood sugar control. Later randomized work (including a JAMA-published trial led by Stanley) confirmed reductions in visceral fat and liver fat. A small placebo-controlled study in non-HIV adults with abdominal obesity also found a meaningful visceral fat reduction over 26 weeks, hinting at broader potential, though that is far less established than the HIV indication. Side effects can include joint pain, swelling, and increases in IGF-1, and growth-hormone-axis drugs warrant caution in people with cancer history or uncontrolled diabetes. In short: well proven for HIV-associated visceral fat, promising but not approved for general use. | IGF-1 LR3 was developed as a cell culture reagent, and that remains its principal legitimate use: it is sold to laboratories to promote cell growth in bioreactors. There are no published randomized human trials of IGF-1 LR3 for muscle growth, body composition or performance. The animal and in vitro work does show what you would expect, increased protein synthesis and muscle cell proliferation, and there is a genuine human literature on recombinant IGF-1 (mecasermin) for severe IGF-1 deficiency, but mecasermin is a different molecule with different pharmacokinetics and its trial data should not be read across. The two consistent safety themes in the underlying biology are hypoglycemia, because IGF-1 has meaningful cross-reactivity with the insulin receptor, and the theoretical concern that chronically elevated IGF-1 signalling promotes growth of tissue you did not intend to grow, including existing tumors. |
Frequently Asked Questions: Tesamorelin vs IGF-1 LR3
What is the difference between Tesamorelin and IGF-1 LR3?
Tesamorelin is a growth hormone peptide that tesamorelin is a stabilized analog of growth-hormone-releasing hormone (ghrh 1-44) with a chemical modification that protects it from rapid breakdown. it is fda-approved (brand name egrifta) to reduce excess visceral abdominal fat in people with hiv-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online. IGF-1 LR3 is a growth hormone peptide that igf-1 lr3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. it is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. everything below the mechanism section is preclinical work, laboratory use, or community reporting. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or IGF-1 LR3?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while IGF-1 LR3 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and IGF-1 LR3 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and IGF-1 LR3 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.